[Consensus on targeted drug therapy for spondyloarthritis].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Zhonghua nei ke za zhi [Zhonghua Nei Ke Za Zhi] 2023 Jun 01; Vol. 62 (6), pp. 606-618.
  • Publication Type:
    English Abstract; Journal Article
  • Language:
    Chinese
  • Additional Information
    • Corporate Authors:
      National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital); Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association; Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine; Chinese Research Hospital Association Rheumatology and Immunology Professional Committee
    • Source:
      Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 16210490R Publication Model: Print Cited Medium: Print ISSN: 0578-1426 (Print) Linking ISSN: 05781426 NLM ISO Abbreviation: Zhonghua Nei Ke Za Zhi Subsets: MEDLINE
    • Publication Information:
      Publication: : Beijing : Zhonghua yi xue hui
      Original Publication: Beijing : Zhonghua yi xue hui Nei ke xue hui
    • Subject Terms:
      Spondylarthritis*/drug therapy ; Rheumatology*; Humans ; Consensus ; Quality of Life ; Inflammation
    • Abstract:
      Spondyloarthritis (SpA) is a group of chronic inflammatory conditions that predominantly involve the spine and/or peripheral joints. The clinical manifestations of SpA are diverse and disabling, with SpA adversely affecting the quality of life of patients. Many new medications that target cytokines or pathways specific for the pathogenesis of SpA have been developed and these are becoming increasingly important in the treatment of SpA. However, establishing how to identify the target patient population and standardizing the usage of these drugs are critical issues in the clinical application of these "targeted therapies".Under the leadership of National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), the"Consensus on targeted drug therapy for spondyloarthritis" has been developed collaborating with the Rheumatology and Immunology Physicians Committee, Chinese Medical Doctors Association, Rheumatology and Immunology Professional Committee, Chinese Association of Rehabilitation Medicine, Chinese Research Hospital Association Rheumatology and Immunology Professional Committee. This consensus was developed with evidence-based methodology and followed the international standard for consensus development.
    • Grant Information:
      2021-I2M-1-005 Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
    • Contributed Indexing:
      Local Abstract: [Publisher, Chinese] 脊柱关节炎（SpA）是一组以中轴骨和/或外周关节受累为主的慢性炎症性疾病，临床表现异质性强，是一组致残性疾病，严重影响患者的生活和躯体功能。近年来，一些针对SpA发病中起关键作用的炎性细胞因子和细胞内通路的靶向治疗药物已逐渐成为其重要的治疗手段。但如何针对SpA患者的疾病特点，精准且规范地选择与使用靶向药物，在合理选择的同时兼顾其安全性，使更多SpA患者获益是临床亟待规范的问题。国家皮肤与免疫疾病临床医学研究中心（北京协和医院）联合中国医师协会风湿免疫专科医师分会、中国康复医学会风湿免疫专业委员会和中国研究型医院学会风湿免疫专业委员会，依据循证医学证据及共识制定的国际规范制定了本共识，旨在为临床医师安全有效地使用靶向药物提供指引，提高我国SpA的规范治疗水平。.
    • Publication Date:
      Date Created: 20230601 Date Completed: 20230605 Latest Revision: 20230605
    • Publication Date:
      20240829
    • Accession Number:
      10.3760/cma.j.cn112138-20221031-00806
    • Accession Number:
      37263944